| Autor: |
Streiff MB; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Holmstrom B; Moffitt Cancer Center., Angelini D; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., Ashrani A; Mayo Clinic Cancer Center., Elshoury A; Roswell Park Comprehensive Cancer Center., Fanikos J; Dana-Farber/Brigham and Women's Cancer Center., Fertrin KY; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance., Fogerty AE; Massachusetts General Hospital Cancer Center., Gao S; The University of Texas MD Anderson Cancer Center., Goldhaber SZ; Dana-Farber/Brigham and Women's Cancer Center., Gundabolu K; Fred & Pamela Buffett Cancer Center., Ibrahim I; UT Southwestern Simmons Comprehensive Cancer Center., Kraut E; Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Leavitt AD; UCSF Helen Diller Family Comprehensive Cancer Center., Lee A; Yale Cancer Center/Smilow Cancer Hospital., Lee JT; Stanford Cancer Institute., Lim M; Huntsman Cancer Institute at the University of Utah., Mann J; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Martin K; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., McMahon B; University of Colorado Cancer Center., Moriarty J; UCLA Jonsson Comprehensive Cancer Center., Morton C; Vanderbilt-Ingram Cancer Center., Ortel TL; Duke Cancer Institute., Paschal R; O'Neal Comprehensive Cancer Center at UAB., Schaefer J; University of Michigan Rogel Cancer Center., Shattil S; UC San Diego Moores Cancer Center., Siddiqi T; City of Hope National Medical Center., Sudheendra D; Abramson Cancer Center at the University of Pennsylvania., Williams E; University of Wisconsin Carbone Cancer Center; and., Hollinger L; National Comprehensive Cancer Network., Nguyen MQ; National Comprehensive Cancer Network. |
| Abstrakt: |
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed. |
